Aktis Oncology (NASDAQ:AKTS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Aktis Oncology (NASDAQ:AKTS) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $34.00.

Several brokerages have recently commented on AKTS. William Blair began coverage on Aktis Oncology in a research note on Wednesday, April 29th. They set an “outperform” rating for the company. HC Wainwright lifted their target price on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Weiss Ratings downgraded Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research note on Tuesday, June 9th. Finally, Raymond James Financial began coverage on Aktis Oncology in a research note on Monday. They set a “strong-buy” rating and a $40.00 target price for the company.

Aktis Oncology Stock Up 9.4%

Shares of NASDAQ AKTS opened at $22.63 on Wednesday. Aktis Oncology has a 12 month low of $14.72 and a 12 month high of $29.16. The business’s 50 day simple moving average is $19.40.

Aktis Oncology (NASDAQ:AKTS) last issued its earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The firm had revenue of $1.87 million during the quarter. On average, research analysts expect that Aktis Oncology will post -1.62 EPS for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.